Clinical Trial

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We design this trial to evaluate the safety and efficacy of Serplulimab plus chemotherapy in SCLC transformed from EGFR-mutated NSCLC after treatment.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-29
notable Enrollment increased: 36 -> 66 participants 2026-05-07
Trial Details
NCT Number NCT05957510
Lead Sponsor Guangdong Association of Clinical Trials
Collaborators: Guangdong Provincial People's Hospital
Conditions Small-cell Lung Cancer
Enrollment 66 participants
Start Date 2023-07-07
Primary Completion 2026-07-02 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28